Immunomodulatory News and Research

RSS

$SIRIUS supports single-agent daratumumab in refractory multiple myeloma$

SIRIUS supports single-agent daratumumab in refractory multiple myeloma

Phase II trial results show that daratumumab monotherapy elicits responses and has a favourable adverse event profile in heavily-pretreated, refractory multiple myeloma patients.

19 Jan 2016

HBI-8000 granted orphan drug designation in Japan for treatment of peripheral T-cell lymphoma

HUYA Bioscience International, Founder, CEO & Executive Chair, Dr. Mireille Gillings today announced that the Ministry of Health, Labour and Welfare granted HBI-8000 orphan drug designation in Japan for peripheral T-cell lymphoma (PTCL).

22 Dec 2015

Scientists reveal major players in severe muscle damage caused by sepsis

Scientists from the Institut Pasteur, Paris Descartes University, Sainte-Anne Hospital and the CNRS have recently published a paper in Nature Communications in which they reveal major players in the severe muscle damage caused by sepsis, or septicemia, which explains why many patients suffer debilitating muscle impairment long-term after recovery.

17 Dec 2015

Exposure to farm animals, pets in early childhood modifies allergy-related immunological mechanisms

Exposure to farm animals in early childhood modifies the key allergy-related immunological mechanisms, shows a recent study from the University of Eastern Finland. The study provides new insight into the role of dendritic cells and cytokine production in particular.

15 Dec 2015

Combination treatment provides effective one-two punch against prostate cancer

Results from a long-term clinical trial conducted by cancer researchers at Houston Methodist Hospital show that combining radiation treatment with "suicide gene therapy," a technique in which prostate cancer cells are genetically modified so they signal a patient's immune system to attack them, provides a safe and effective one-two punch against the disease.

12 Dec 2015

Virginia Tech researchers study how specific cytokine influences gene expression patterns in T helper cells

Environment can make all the difference in behavior - even at the cellular level. Scientists at the Virginia Tech Carilion Research Institute have discovered even a small shift in environmental factors can change how a cell in the immune system matures.

28 Oct 2015

HUYA Bioscience International expands HBI-8000 clinical trials for breast cancer

HUYA Bioscience International (HUYA) today announced expanding clinical trials with its lead cancer drug, HBI-8000, starting with a Phase 1 combination trial in support of a breast cancer program to be conducted in the United States.

3 Sep 2015

Continuous therapy improves multiple myeloma outcomes

Patients with newly diagnosed multiple myeloma receive significant progression-free and overall survival benefits from continuous treatment compared with fixed-duration therapy, suggests a pooled analysis.

27 Aug 2015

Experts shed light on the exciting field of therapy research for inflammatory diseases

What is happening in the treatment research of the inflammatory autoimmune diseases? Experts from several fields of medicine shed their light on the exciting field of therapy research for the inflammatory (autoimmune) diseases.

27 Aug 2015

Transplanting mesenchymal stromal cells derived from amniotic membranes can benefit eye diseases

A team of researchers in South Korea has successfully transplanted mesenchymal stromal cells (MSCs) derived from human amniotic membranes of the placenta (AMSCs) into laboratory mice modeled with oxygen-induced retinopathy (a murine model used to mimic eye disease).

20 Aug 2015

IP10 levels linked to HBsAg decline during TDF treatment

Baseline serum interferon-inducible protein 10 levels predict hepatitis B surface antigen reduction in patients with hepatitis B e antigen-negative chronic hepatitis B virus infection treated with tenofovir disoproxil fumarate, findings indicate.

4 Aug 2015

Array Biopharma reports strong fourth quarter and full year 2015 financial results

Array BioPharma Inc. today reported results for the fourth quarter and full year of its fiscal year ended June 30, 2015.

3 Aug 2015

New research identifies potential treatment for primary effusion lymphoma

New research from the University of Southern California Norris Comprehensive Cancer Center has identified a potential treatment for a rare but previously incurable form of lymphoma that is observed primarily in patients with HIV/AIDS infection.

8 Jul 2015

Hepatic ALT flares linked to HBsAg clearance

Hepatic alanine aminotransferase flares are associated with rapid decline and greater annual reductions of hepatitis B surface antigen in patients with chronic hepatitis B virus infection who achieve HBsAg seroclearance, say Japanese researchers.

30 Jun 2015

New Christian Doppler Laboratory for Complement Research opens at MedUni Vienna

Today the new Christian Doppler Laboratory for Complement Research was opened at the Center for Pathophysiology, Infectiology and Immunology at MedUni Vienna. The research institute, which is funded by the Federal Ministry of Science, Research and Economic Affairs (BMWFW) is concentrating on a special protein that is thought to play an important role in controlling excessive immune reactions.

26 Jun 2015

Novartis presents positive Phase III results of Farydak therapy at EHA

Novartis today presented results from a pivotal Phase III clinical trial exploratory subgroup analysis showing a 7.8-month improvement in median progression-free survival when using Farydak in combination with bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma who had received two or more prior regimens, including bortezomib and an immunomodulatory agent.

16 Jun 2015

Janssen begins rolling submission of daratumumab BLA to FDA for treatment of patients with multiple myeloma

Janssen Research & Development, LLC has initiated the rolling submission of its Biologic License Application (BLA) for daratumumab to the U.S. Food and Drug Administration (FDA) for the treatment of patients with multiple myeloma who have received at least three prior lines of therapy, including a proteasome inhibitor (PI) and an immunomodulatory agent (IMiD), or who are double refractory to a PI and an IMiD.

7 Jun 2015

$Elotuzumab boosts response in relapsed, refractory multiple myeloma$